The Blood Service convenes an annual Strategic Blood Forum, providing clinical and government stakeholders an update on our activities, particularly those related to patient safety and service issues. The meeting is an opportunity to obtain feedback from our clinical colleagues and representatives from professional societies and the specialist colleges regarding areas of priority for them.
This year’s Forum was held in Sydney on Wednesday 10 February.
Presentations and discussions on the day covered clinical and operational issues relating to the current debate about the red cell storage lesion and the age of red cells at the time of transfusion, the rationale for and implications of the Blood Service’s implementation of fully automated nucleic acid testing (NAT) and NAT for hepatitis B, the Blood Service’s approach to TRALI risk reduction and an overview of clinical practice trends in the use of intravenous immunoglobulin.
Updates were also provided on the results to date and the operational and clinical impacts of platelet bacterial contamination screening, the aims and progress of the Blood Service Re-engineer our Supply and Service (RoSS) Program, and clinical and other research activities which the Blood Service is currently undertaking, including the evaluation of currently available pathogen inactivation technologies.
There was considerable discussion during the stakeholder feedback sessions, covering issues such as the possible utility and the logistics of provision of frozen blood, the availability of blood and blood products in rural and remote areas, massive transfusion protocols and the clinical desirability of having access to a fibrinogen concentrate and importance of establishing patient blood management programs.
Further details regarding specific issues discussed during the Forum will be published in our next MediLink newsletter.